Why ManKind (MNKD) Stock Is Soaring Today

NEW YORK (TheStreet) -- ManKind (MNKD) shares are spiking, up 10.6% to $11.06, on Monday after the FDA approved the company's inhaled insulin drug Afrezza.

Wall Street analysts believe that the drug could generate peak yearly sales of $600 million for the company.

Must ReadWarren Buffett's 25 Favorite Stocks

MNKD Chart

MNKD data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.


More from Markets

Tencent Posts Big Second Quarter Earning Miss as Game Problems Persist

Tencent Posts Big Second Quarter Earning Miss as Game Problems Persist

Stocks Slide, Dollar Rises as China Markets, Lira Crisis Keep Investors Cautious

Stocks Slide, Dollar Rises as China Markets, Lira Crisis Keep Investors Cautious

U.K. Inflation Rises for First Time in 8 Months as Pound Continues to Tumble

U.K. Inflation Rises for First Time in 8 Months as Pound Continues to Tumble

RBS Confirms First Dividend In a Decade After $4.9 Billion DoJ Settlement

RBS Confirms First Dividend In a Decade After $4.9 Billion DoJ Settlement

Tesla's Musk Has Serious Dell Envy; Hedge Funds Reveal Portfolio Changes - ICYMI

Tesla's Musk Has Serious Dell Envy; Hedge Funds Reveal Portfolio Changes - ICYMI